Key result
Universal newborn screening with presymptomatic SMA therapy proves cost-effective at ~2.1 million NTD/QALY.
Why the study?
Universal newborn screening enables presymptomatic disease-modifying therapy for spinal muscular atrophy but increases upfront costs, leaving its cost-effectiveness in Taiwan unestablished.
Is universal newborn screening with presymptomatic disease-modifying therapy cost-effective compared to clinical identification with symptomatic therapy for spinal muscular atrophy in Taiwan?
Is universal newborn screening with presymptomatic disease-modifying therapy cost-effective compared to clinical identification with symptomatic therapy for spinal muscular atrophy in Taiwan?
Universal newborn screening for SMA with presymptomatic disease-modifying therapy is likely cost-effective in Taiwan from both payer and societal perspectives.
Answers are grounded in this paper and cite their sources.
Supports cost-effectiveness of SMA newborn screening in Taiwan; leaves open prospective validation before broader adoption.
OBJECTIVES: Spinal muscular atrophy (SMA) is a rare neuromuscular disorder and an important genetic cause of infant mortality. Universal newborn screening (NBS) enables presymptomatic disease-modifying therapy (DMT) but increases upfront costs. This study evaluated the cost-effectiveness of universal SMA NBS in Taiwan. METHODS: This study built a state-transition simulation model for a hypothetical SMA birth cohort using local epidemiology and costs and published clinical inputs. Strategies were as follows: (1) NBS with presymptomatic DMTs and (2) clinical identification (CI) with symptomatic DMTs. DMTs included nusinersen, onasemnogene abeparvovec, and risdiplam (reimbursed by Taiwan's National Health Insurance). Incremental costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were estimated over 10-year and lifetime (90-year) horizons from Taiwan's payer and societal perspectives. The willingness-to-pay (WTP) threshold was 3 times Taiwan's 2022 GDP per capita (New Taiwan Dollar (NTD) 2 917 650/QALY). One-way, probabilistic sensitivity, and scenario analyses assessed uncertainty. RESULTS: All ICERs were below WTP threshold. From the payer perspective, ICERs for NBS with presymptomatic DMT versus CI with symptomatic DMT were NTD 1 157 970 (USD 38 599) /QALY (10 years) and NTD 2 108 499 (USD 70 283)/QALY (lifetime). From the societal perspective, ICERs were NTD 261 789 (USD 8726)/QALY (10 years) and NTD 1 494 002 (USD 49 800)/QALY (lifetime). Results were most sensitive to DMT costs (particularly nusinersen and risdiplam) and health-state utility values. CONCLUSIONS: Universal SMA NBS with presymptomatic DMT is likely cost-effective in Taiwan from both payer and societal perspectives under the WTP threshold, supporting earlier treatment to slow progression and improve quality of life.
No takes yet. Share an insight, caveat, or question.
Chiang et al. (2026) studied Spinal muscular atrophy (SMA). Universal newborn screening with presymptomatic disease-modifying therapy vs. Clinical identification with symptomatic disease-modifying therapy was evaluated on Incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) (ICER NTD 2 108 499/QALY (lifetime, payer perspective)). Universal newborn screening with presymptomatic therapy for SMA is cost-effective in Taiwan, with a lifetime ICER of NTD 2,108,499/QALY from the payer perspective.
Synapse has enriched 10 related papers. Consider them for comparative context: